modafinil has been researched along with Depression, Involutional in 46 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
Excerpt | Relevance | Reference |
---|---|---|
"Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood." | 9.12 | Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. ( Arora, S; DeBattista, C; Fava, M; Hughes, RJ; Thase, ME, 2006) |
"Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue." | 9.12 | Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007) |
"Modafinil combined with an SSRI at treatment initiation may enhance the onset and degree of symptom benefit in patients with MDD and fatigue." | 9.11 | Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004) |
"These findings suggest that modafinil is a well-tolerated and potentially effective augmenting agent for SSRI partial responders with fatigue and sleepiness." | 9.11 | A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. ( DeBattista, C; Fava, M; Thase, ME, 2005) |
"Modafinil may be a useful adjunct therapy for the short-term management of residual fatigue and sleepiness in patients who are partial responders to antidepressant therapy." | 9.10 | Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. ( DeBattista, C; Doghramji, K; Fieve, RR; Menza, MA; Rosenthal, MH, 2003) |
"This is a case report of a patient with narcolepsy treated simultaneously with modafinil and tranylcypromine." | 7.72 | Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. ( Clemons, WE; Makela, E; Young, J, 2004) |
"19] after taking 200 mg versus 100 mg and 0 mg of modafinil, while fluency increased linearly with dosage at a trend level [F(1,18) = 4." | 7.11 | A multi-pronged investigation of option generation using depression, PET and modafinil. ( Ang, YS; Belleau, EL; Boyden, S; Breiger, M; Brunner, D; Cusin, C; Dillon, DG; El Fakhri, G; Fava, M; Gelda, SE; Hayden, E; Hooker, J; Jahan, A; Kang, MS; Levine, MT; Meyer, AK; Normandin, M; Petibon, Y; Pizzagalli, DA; Schroder, H, 2022) |
"Twelve weeks of modafinil augmentation relieved excessive sleepiness, reduced fatigue, and improved patients' overall clinical condition, including mood." | 5.12 | Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. ( Arora, S; DeBattista, C; Fava, M; Hughes, RJ; Thase, ME, 2006) |
"Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue." | 5.12 | Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. ( Crits-Christoph, P; Dunlop, BW; Evans, DL; Gallop, RJ; Garlow, SJ; Hirschowitz, J; Ninan, PT; Rickels, K; Solvason, HB, 2007) |
"Modafinil combined with an SSRI at treatment initiation may enhance the onset and degree of symptom benefit in patients with MDD and fatigue." | 5.11 | Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004) |
"These findings suggest that modafinil is a well-tolerated and potentially effective augmenting agent for SSRI partial responders with fatigue and sleepiness." | 5.11 | A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. ( DeBattista, C; Fava, M; Thase, ME, 2005) |
"Modafinil may be a useful adjunct therapy for the short-term management of residual fatigue and sleepiness in patients who are partial responders to antidepressant therapy." | 5.10 | Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. ( DeBattista, C; Doghramji, K; Fieve, RR; Menza, MA; Rosenthal, MH, 2003) |
"The use of traditional psychostimulants (methylphenidate and dexamphetamine) and stimulant-like drugs (modafinil and armodafinil) for the treatment of depression is a growing concern given the lack of research evidence supporting their effectiveness." | 4.93 | Stimulants for depression: On the up and up? ( Bassett, D; Boyce, P; Byrow, Y; Hopwood, M; Lyndon, W; Malhi, GS; Mulder, R; Murray, G; Porter, R; Singh, A, 2016) |
"Modafinil is an effective augmentation strategy for acute depressive episodes, including for symptoms of fatigue, in both unipolar and bipolar disorders." | 4.89 | Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. ( Costafreda, SG; Fu, CH; Goss, AJ; Kaser, M; Sahakian, BJ, 2013) |
"This is a case report of a patient with narcolepsy treated simultaneously with modafinil and tranylcypromine." | 3.72 | Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. ( Clemons, WE; Makela, E; Young, J, 2004) |
"19] after taking 200 mg versus 100 mg and 0 mg of modafinil, while fluency increased linearly with dosage at a trend level [F(1,18) = 4." | 3.11 | A multi-pronged investigation of option generation using depression, PET and modafinil. ( Ang, YS; Belleau, EL; Boyden, S; Breiger, M; Brunner, D; Cusin, C; Dillon, DG; El Fakhri, G; Fava, M; Gelda, SE; Hayden, E; Hooker, J; Jahan, A; Kang, MS; Levine, MT; Meyer, AK; Normandin, M; Petibon, Y; Pizzagalli, DA; Schroder, H, 2022) |
" We evaluated the effect of daily dosing with armodafinil on the pharmacokinetics and safety of the CYP3A4 substrate aripiprazole, an atypical antipsychotic used to treat bipolar I disorder." | 2.80 | Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults. ( Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R, 2015) |
" Adverse events (AEs) observed in > 5% of either the armodafinil 150 mg or placebo groups and more frequently with 150 mg armodafinil were diarrhea (9% [17/198] vs 7% [13/199]), and nausea (6% [11/198] vs 5% [9/199]), respectively." | 2.79 | Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. ( Calabrese, JR; Frye, MA; Ketter, TA; Yang, R, 2014) |
"Armodafinil was not associated with an increased incidence and/or severity of suicidality, depression, or mania or with changes in metabolic profile measurements." | 2.75 | Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. ( Calabrese, JR; Frye, MA; Ketter, TA; Tiller, JM; Yang, R; Youakim, JM, 2010) |
"Modafinil is a wake-promoting agent approved by the Federal Drug Administration for the treatment of narcolepsy." | 2.71 | A prospective trial of modafinil as an adjunctive treatment of major depression. ( DeBattista, C; Ghebremichael, R; Lembke, A; Poirier, J; Solvason, HB, 2004) |
"Modafinil has proven to be effective in the treatment of residual symptoms of unipolar and bipolar depression such as fatigue, excessive sleepiness and some cognitive impairment." | 2.66 | The role of eugeroics in the treatment of affective disorders. ( Cubała, WJ; Urban, AE, 2020) |
"Modafinil was associated with improvements in executive functioning after 4 weeks of open-label adjunctive treatment in currently depressed participants." | 2.61 | The Potential Procognitive Effects of Modafinil in Major Depressive Disorder: A Systematic Review. ( Bhat, V; Kennedy, SH; McInerney, SJ; Vaccarino, SR, 2019) |
" Approaches to the management of residual symptoms include addressing treatment-emergent side effects and co-morbid conditions, optimizing antidepressant dosing and using augmentation therapy." | 2.43 | Pharmacological approaches to the treatment of residual symptoms. ( Fava, M, 2006) |
"Fatigue and sleepiness (hypersomnia) are symptoms that are highly prevalent in patients with major depressive disorder (MDD)." | 2.43 | Symptoms of fatigue and sleepiness in major depressive disorder. ( Baldwin, DS; Papakostas, GI, 2006) |
"Standard antidepressants approved for treating major depressive disorder fail to exert efficacy in bipolar depression." | 1.91 | High-dose armodafinil in treatment-refractory bipolar depression. ( Kwok, WY; Nasrallah, HA; Stephens, V, 2023) |
"Modafinil is a drug with stimulanteffect on the central nervous system by binding to norepinephrineand dopamine transporters and consequently increasing synapticnorepinephrine and dopamine levels." | 1.51 | [Use of Modafinil in Co-existing Major Depression and ErectileDysfunction: A Case Report]. ( Karaş, H; Kaşer, M, 2019) |
" Subjects assigned to group 1 received a dose of carbamazepine (200 mg) alone and a dose after pretreatment with daily dosing of armodafinil (titrated to 250 mg/d)." | 1.42 | Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults. ( Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R, 2015) |
"Modafinil has a novel mechanism of action and may have antidepressant properties." | 1.33 | A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. ( Price, CS; Taylor, FB, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 24 (52.17) | 29.6817 |
2010's | 19 (41.30) | 24.3611 |
2020's | 3 (6.52) | 2.80 |
Authors | Studies |
---|---|
Ang, YS | 1 |
Cusin, C | 1 |
Petibon, Y | 1 |
Dillon, DG | 1 |
Breiger, M | 1 |
Belleau, EL | 1 |
Normandin, M | 1 |
Schroder, H | 1 |
Boyden, S | 1 |
Hayden, E | 1 |
Levine, MT | 1 |
Jahan, A | 1 |
Meyer, AK | 1 |
Kang, MS | 1 |
Brunner, D | 1 |
Gelda, SE | 1 |
Hooker, J | 1 |
El Fakhri, G | 1 |
Fava, M | 5 |
Pizzagalli, DA | 1 |
Kwok, WY | 1 |
Stephens, V | 1 |
Nasrallah, HA | 1 |
Karaş, H | 1 |
Kaşer, M | 2 |
Vaccarino, SR | 1 |
McInerney, SJ | 1 |
Kennedy, SH | 2 |
Bhat, V | 1 |
Urban, AE | 1 |
Cubała, WJ | 1 |
McIntyre, RS | 1 |
Lee, Y | 1 |
Zhou, AJ | 1 |
Rosenblat, JD | 1 |
Peters, EM | 1 |
Lam, RW | 1 |
Rong, C | 1 |
Jerrell, JM | 1 |
Goss, AJ | 1 |
Costafreda, SG | 1 |
Sahakian, BJ | 1 |
Fu, CH | 1 |
Calabrese, JR | 2 |
Frye, MA | 2 |
Yang, R | 5 |
Ketter, TA | 2 |
El-Mallakh, RS | 1 |
Ostacher, MJ | 1 |
Darwish, M | 2 |
Bond, M | 2 |
Hellriegel, ET | 2 |
Robertson, P | 2 |
Andrade, C | 1 |
Malhi, GS | 1 |
Byrow, Y | 1 |
Bassett, D | 1 |
Boyce, P | 1 |
Hopwood, M | 1 |
Lyndon, W | 1 |
Mulder, R | 1 |
Porter, R | 1 |
Singh, A | 1 |
Murray, G | 1 |
Otto, MW | 1 |
Lee, J | 1 |
Hofmann, SG | 1 |
Hearon, BA | 1 |
Smits, JA | 1 |
Rosenfield, D | 1 |
Wright, JH | 1 |
Ng, B | 2 |
Pae, CU | 1 |
Patkar, AA | 1 |
Masand, PS | 1 |
IsHak, WW | 1 |
Davis, M | 1 |
Jeffrey, J | 1 |
Balayan, K | 1 |
Pechnick, RN | 1 |
Bagot, K | 1 |
Rapaport, MH | 1 |
Krystal, AD | 1 |
Harsh, JR | 1 |
Yang, RR | 1 |
Rippon, GA | 1 |
Lankford, DA | 1 |
Beck, J | 1 |
Hemmeter, U | 1 |
Brand, S | 1 |
Muheim, F | 1 |
Hatzinger, M | 1 |
Holsboer-Trachsler, E | 1 |
Black, W | 1 |
Hoey, P | 1 |
Mayze, T | 1 |
Youakim, JM | 1 |
Tiller, JM | 1 |
Abolfazli, R | 1 |
Hosseini, M | 1 |
Ghanizadeh, A | 1 |
Ghaleiha, A | 1 |
Tabrizi, M | 1 |
Raznahan, M | 1 |
Golalizadeh, M | 1 |
Akhondzadeh, S | 1 |
Howland, RH | 1 |
Videbech, P | 1 |
Markovitz, PJ | 1 |
Wagner, S | 1 |
Schillerstrom, JE | 1 |
Seaman, JS | 1 |
DeBattista, C | 5 |
Doghramji, K | 1 |
Menza, MA | 2 |
Rosenthal, MH | 1 |
Fieve, RR | 1 |
Lembke, A | 1 |
Solvason, HB | 2 |
Ghebremichael, R | 1 |
Poirier, J | 1 |
Even, C | 1 |
Friedman, S | 1 |
Dardennes, R | 1 |
Guelfi, JD | 1 |
Ninan, PT | 2 |
Hassman, HA | 1 |
Glass, SJ | 1 |
McManus, FC | 1 |
Clemons, WE | 1 |
Makela, E | 1 |
Young, J | 1 |
Thase, ME | 2 |
Price, CS | 1 |
Taylor, FB | 1 |
Arora, S | 1 |
Hughes, RJ | 1 |
Luborzewski, A | 1 |
Regen, F | 1 |
Schindler, F | 1 |
Anghelescu, I | 1 |
Block, J | 1 |
Baldwin, DS | 1 |
Papakostas, GI | 1 |
Berlim, MT | 1 |
Turecki, MG | 1 |
Dunlop, BW | 1 |
Crits-Christoph, P | 1 |
Evans, DL | 1 |
Hirschowitz, J | 1 |
Rickels, K | 1 |
Garlow, SJ | 1 |
Gallop, RJ | 1 |
Fountoulakis, KN | 1 |
Siamouli, M | 1 |
Panagiotidis, P | 1 |
Magiria, S | 1 |
Kantartzis, S | 1 |
Iacovides, A | 1 |
Kaprinis, GS | 1 |
Oulis, P | 1 |
Kouzoupis, AV | 1 |
Kontoangelos, K | 1 |
Pachou, E | 1 |
Masdrakis, VG | 1 |
Soldatos, CR | 1 |
Kaufman, KR | 1 |
Fitzsimmons, A | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder[NCT01072929] | Phase 3 | 433 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
Improving Therapeutic Learning in Depression: Proof of Concept[NCT02376257] | Phase 2 | 36 participants (Actual) | Interventional | 2014-09-16 | Completed | ||
Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome With Major Depressive Disorder or Dysthymic Disorder[NCT00518986] | Phase 4 | 249 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
An 8 Week Double Blind, Placebo-Controlled, Parallel Group, Fixed Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder[NCT00481195] | Phase 2 | 257 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
Does Modafinil Have Pro-cognitive Effects in Those With Residual Cognitive Impairment Despite Remitted Depression?[NCT03620253] | Phase 3 | 9 participants (Actual) | Interventional | 2018-10-15 | Terminated (stopped due to Principal Investigator left study site) | ||
Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
HAM-A measures the severity of anxiety symptoms. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Negative change from baseline scores indicate a decrease in severity of anxiety. (NCT01072929)
Timeframe: Day 0 (baseline), last postbaseline observation (up to 8 weeks)
Intervention | units on a scale (Mean) |
---|---|
Placebo | -4.2 |
Armodafinil 150 mg/Day | -4.2 |
Armodafinil 200 mg/Day | -3.3 |
The ISI is a participant-rated, 7-item questionnaire designed to assess the severity of the participant's insomnia. Each item is ranked 0 (none) through 4 (very severe) and has a descriptor associated with each severity level. Total range is 0 (no insomnia) to 28 (very severe insomnia). Responses to each item are added to obtain a total score to determine the severity of insomnia. Negative change from baseline scores indicate a decrease in severity of insomnia. (NCT01072929)
Timeframe: Day 0 (baseline), last postbaseline observation (up to 8 weeks)
Intervention | units on a scale (Mean) |
---|---|
Placebo | -6.4 |
Armodafinil 150 mg/Day | -6.5 |
Armodafinil 200 mg/Day | -5.6 |
The YMRS is a clinician-rated, 11-item checklist used to measure the severity of manic episodes. Information for assigning scores is gained from the participant's subjective reported symptoms over the previous 48 hours and from clinical observation during the interview. Seven items are ranked 0 through 4 and have descriptors associated with each severity level. Four items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 through 8 and have descriptors for every second increment. The total scale is 0-60. A score of ≤12 indicates remission of manic symptoms, and higher scores indicate greater severity of mania. Negative change from baseline scores indicate a decrease in severity of mania. (NCT01072929)
Timeframe: Day 0 (baseline), last postbaseline observation (up to 8 weeks)
Intervention | units on a scale (Mean) |
---|---|
Placebo | -1.1 |
Armodafinil 150 mg/Day | -1.1 |
Armodafinil 200 mg/Day | -1.0 |
"The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.~Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression." (NCT01072929)
Timeframe: Day 0 (baseline), Week 8
Intervention | units on a scale (Least Squares Mean) |
---|---|
Placebo | -17.9 |
Armodafinil 150 mg/Day | -21.7 |
All Armodafinil | -20.8 |
The CGI-S is an observer-rated scale that measures illness severity on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). Negative change from baseline values indicate improvement in the severity of depression. (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Intervention | units on a scale (Mean) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 28) | Week 4 (178, 168, 27) | Week 6 (160, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (196, 197, 31) | |
Armodafinil 150 mg/Day | -0.4 | -0.6 | -0.9 | -1.4 | -1.6 | -1.7 | -1.4 |
Armodafinil 200 mg/Day | -0.5 | -0.5 | -0.8 | -0.9 | -1.1 | -1.3 | -1.2 |
Placebo | -0.3 | -0.5 | -0.9 | -1.2 | -1.3 | -1.5 | -1.3 |
The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression. (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Intervention | units on a scale (Mean) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (160, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (196, 197, 31) | |
Armodafinil 150 mg/Day | -2.8 | -4.4 | -6.5 | -8.1 | -8.6 | -9.4 | -8.0 |
Armodafinil 200 mg/Day | -4.1 | -5.0 | -6.4 | -7.4 | -7.6 | -7.3 | -6.6 |
Placebo | -2.3 | -3.8 | -5.6 | -6.9 | -7.2 | -7.6 | -6.6 |
"The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.~Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression." (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Intervention | units on a scale (Mean) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 193, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (160, 158, 21) | Week 7 (152, 144, 19) | Week 8 (155, 150, 24) | Endpoint (196, 197, 31) | |
Armodafinil 150 mg/Day | -6.5 | -10.4 | -15.6 | -19.7 | -21.7 | -23.3 | -20.2 |
Armodafinil 200 mg/Day | -9.8 | -12.9 | -15.3 | -17.4 | -17.8 | -17.0 | -15.8 |
Placebo | -6.1 | -10.2 | -14.3 | -18.3 | -18.8 | -19.7 | -17.3 |
The Global Assessment of Functioning (GAF) is a numeric scale (1 through 100) used by mental health clinicians and physicians to rate subjectively the social, occupational, and psychological functioning of adults, e.g., how well or adaptively one is meeting various problems-in-living. Ratings of 1 - 10 mean the participant is in persistent danger of severely hurting self or others (e.g., recurrent violence) or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death. Ratings of 91 - 100 indicate no symptoms, and the participant exhibits superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many positive qualities. Positive change from baseline values indicate improvement in functioning. (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 4, 8, and last postbaseline observation (up to 8 weeks)
Intervention | units on a scale (Mean) | ||
---|---|---|---|
Week 4 (175, 168, 27) | Week 8 (153, 150, 24) | Endpoint (191, 189, 29) | |
Armodafinil 150 mg/Day | 7.7 | 15.6 | 12.8 |
Armodafinil 200 mg/Day | 8.9 | 13.6 | 12.2 |
Placebo | 7.2 | 11.4 | 10.2 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Aborted Attempt question records whether the participant began to take steps toward making a suicide attempt but stops themselves before starting the potentially self-injurious act since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (159, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (197, 198, 31) | |
Armodafinil 150 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Actual Attempt question records whether the participant committed a potentially self-injurious act with at least some wish to die since the last visit. (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (159, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (197, 198, 31) | |
Armodafinil 150 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Completed Suicide question records whether the participant intentionally causing his/her's own death since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (159, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (197, 198, 31) | |
Armodafinil 150 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Interrupted Attempt question records whether the participant was interrupted by an outside circumstance from starting the potentially self-injurious act with at least some wish to die since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (159, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (197, 198, 31) | |
Armodafinil 150 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Non-Suicidal Self-Injurious Behavior question records whether the participant committed a potentially self-injurious act that was not associated with a wish to die since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (159, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (197, 198, 31) | |
Armodafinil 150 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Preparatory Acts or Behavior question records whether the participant exhibited acts or preparations towards imminently making a suicide attempt since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (159, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (197, 198, 31) | |
Armodafinil 150 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Behavior - Suicidal Behavior question records whether in the clinician's opinion, the participant exhibited suicidal behavior since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (159, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (197, 198, 31) | |
Armodafinil 150 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act question records whether the participant endorses thoughts of suicide and has thought of at least one method but has no specific plan of action since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (3, 6, 1) | Week 2 (2, 2, 0) | Week 4 (2, 4, 0) | Week 6 (0, 2, 0) | Week 7 (1, 0, 0) | Week 8 (0, 2, 0) | Endpoint (11, 11, 1) | |
Armodafinil 150 mg/Day | 0 | 0 | 1 | 0 | 0 | 0 | 3 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Non-Specific Active Suicidal Thoughts question records whether the participant shares general non-specific thoughts of wanting to end one's life/commit suicide since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (159, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (197, 198, 31) | |
Armodafinil 150 mg/Day | 1 | 1 | 1 | 1 | 0 | 0 | 3 |
Armodafinil 200 mg/Day | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Some Intent to Act Without a Specific Plan question records whether the participant has active suicidal thoughts of killing oneself and reports having some intent to act on such thoughts since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (3, 6, 1) | Week 2 (2, 2, 0) | Week 4 (2, 4, 0) | Week 6 (0, 2, 0) | Week 7 (1, 0, 0) | Week 8 (0, 2, 0) | Endpoint (11, 11, 1) | |
Armodafinil 150 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Specific Plan and Intent question records whether the participant has active suicidal thoughts of killing oneself with details of plan fully or partially worked out and the participant has some intent to carry out the plan since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (3, 6, 1) | Week 2 (2, 2, 0) | Week 4 (2, 4, 0) | Week 6 (0, 2, 0) | Week 7 (1, 0, 0) | Week 8 (0, 2, 0) | Endpoint (11, 11, 1) | |
Armodafinil 150 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Armodafinil 200 mg/Day | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
"The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.~The Suicidal Ideation - Wish to Be Dead question records whether the participant endorses thoughts about a wish to dead or not alive anymore, or a wish to fall asleep and not wake up since the last visit." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 194, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (159, 158, 21) | Week 7 (152, 145, 19) | Week 8 (155, 150, 24) | Endpoint (197, 198, 31) | |
Armodafinil 150 mg/Day | 7 | 4 | 5 | 5 | 0 | 2 | 7 |
Armodafinil 200 mg/Day | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Placebo | 4 | 2 | 3 | 0 | 1 | 1 | 6 |
"AEs were graded by the investigator for severity on a three-point scale: mild, moderate and severe. Causality is graded as either related or not related. A serious adverse event (SAE) is an AE resulting in death, a life-threatening adverse event, hospitalization, a persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may require medical intervention to prevent any of the previous results.~Protocol-defined adverse events requiring expedited reporting included skin rash, hypersensitivity reaction, emergent suicidal ideation or suicide attempt, and psychosis." (NCT01072929)
Timeframe: Day 1 to Week 9
Intervention | participants (Number) | ||||||
---|---|---|---|---|---|---|---|
>=1 adverse event | Severe adverse event | Treatment-related adverse event | Deaths | Other serious adverse events | Withdrawn from study due to adverse events | Protocol-defined adverse events | |
Armodafinil 150 mg/Day | 95 | 6 | 44 | 0 | 3 | 11 | 7 |
Armodafinil 200 mg/Day | 23 | 4 | 13 | 1 | 2 | 2 | 0 |
Placebo | 91 | 8 | 44 | 0 | 5 | 7 | 4 |
"A participant in remission was defined as a participant with an IDS-C30 total score of 11 or less.~The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.~Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression." (NCT01072929)
Timeframe: Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Intervention | percentage of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 193, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (160, 158, 21) | Week 7 (152, 144, 19) | Week 8 (155, 150, 24) | Endpoint (196, 197, 31) | |
Armodafinil 150 mg/Day | 1 | 2 | 4 | 15 | 17 | 28 | 21 |
Armodafinil 200 mg/Day | 3 | 7 | 11 | 10 | 16 | 17 | 13 |
Placebo | 1 | 2 | 6 | 16 | 22 | 22 | 17 |
"A responder is a participant with a ≥50% decrease or greater from baseline in the total score of the IDS-C30. The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.~Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression." (NCT01072929)
Timeframe: Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)
Intervention | percentage of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Week 1 (191, 193, 29) | Week 2 (188, 181, 27) | Week 4 (178, 168, 27) | Week 6 (160, 158, 21) | Week 7 (152, 144, 19) | Week 8 (155, 150, 24) | Endpoint (196, 197, 31) | |
Armodafinil 150 mg/Day | 6 | 8 | 26 | 39 | 51 | 55 | 46 |
Armodafinil 200 mg/Day | 10 | 26 | 37 | 43 | 47 | 42 | 39 |
Placebo | 4 | 12 | 23 | 38 | 39 | 39 | 34 |
Higher scores reflect greater recall of Wechsler Memory Scale (WMS) Story B content assessed one week after last rehearsal. Possible scores range from 0 to 25. (NCT02376257)
Timeframe: Week 2 and Week 3
Intervention | units on a scale (Mean) | |
---|---|---|
Week 2 | Week 3 | |
100 mg Modafinil | 4.4 | 12.8 |
250 mg DCS | 1.8 | 9.5 |
Placebo | 5.0 | 13.6 |
1 Week Delayed Recall of a Threat-Related Story. Scores can range from 0 to 74, with higher scores reflect greater memory for story items. (NCT02376257)
Timeframe: Week 2 and Week 3
Intervention | units on a scale (Mean) | |
---|---|---|
Week 2 | Week 3 | |
100 mg Modafinil | 21.3 | 37.3 |
250 mg DCS | 13.5 | 25.0 |
Placebo | 16.1 | 26.4 |
The examiner reads a list of digits and asks that each digit be read backwards. The score is the total number of trials completed correctly; scores range from 0 to 16. Higher scores indicate better performance. (NCT02376257)
Timeframe: Baseline, Week 1, Week 2, Week 3
Intervention | Number of correct trials (Mean) | |||
---|---|---|---|---|
Baseline | Week 1 | Week 2 | Week 3 | |
100 mg Modafinil | 9.5 | 10.4 | 11.3 | 11.4 |
250 mg DCS | 8.3 | 9.25 | 10.0 | 9.6 |
Placebo | 11.3 | 12.2 | 12.1 | 11.7 |
The Hopkins Verbal Learning Test (HVLT) consists of a 12-item word list, composed of four words from each of the three semantic categories. The patient's free recall of the list is recorded. The same procedure is repeated for two more trials. The total recall score for the third trial was used as the recorded score and ranged from a minimum of zero to a maximum of 12 correct answers. (NCT02376257)
Timeframe: Baseline, Week 1, Week 2, Week 3
Intervention | Number of words recalled (Mean) | |||
---|---|---|---|---|
Baseline | Week 1 | Week 2 | Week 3 | |
100 mg Modafinil | 9.6 | 9.9 | 9.7 | 10.1 |
250 mg DCS | 8.5 | 7.8 | 8.7 | 8.8 |
Placebo | 9.6 | 9.4 | 9.6 | 9.4 |
Immediate recall score of items from the Emotional Story presentation. Scores can range from 0 to 74, with higher scores reflect greater memory for story items. (NCT02376257)
Timeframe: Week 1, Week 2, Week 3
Intervention | Number of story units recalled (Mean) | ||
---|---|---|---|
Week 1 | Week 2 | Week 3 | |
100 mg Modafinil | 35.2 | 46.8 | 49.9 |
250 mg DCS | 22.4 | 34.4 | 38.4 |
Placebo | 32.2 | 35.5 | 43.4 |
Immediate Story Recall from the Wechsler Memory Scale Story B. Higher scores reflect greater recall of the story material from the previous week. Possible scores range from 0 to 25. (NCT02376257)
Timeframe: Week 1, Week 2, Week 3
Intervention | Number of story units recalled (Mean) | ||
---|---|---|---|
Week 1 | Week 2 | Week 3 | |
100 mg Modafinil | 17.1 | 17.8 | 21.5 |
250 mg DCS | 14.8 | 17.7 | 18.5 |
Placebo | 16.2 | 18.2 | 21.2 |
A modified Cognitive Therapy Awareness Scale (CTAS) was used to assess delayed memory for cognitive therapy content from the computerized CBT. Higher scores indicate better memory for CBT skills. Scores range from 0 to 40. (NCT02376257)
Timeframe: Week 2 and Week 3
Intervention | Number of correct units of information (Mean) | |
---|---|---|
Week 2 | Week 3 | |
100 mg Modafinil | 26.8 | 29.7 |
250 mg DCS | 25.4 | 28.2 |
Placebo | 24.7 | 28.7 |
This measure assesses the self-reported use of skills from cognitive therapy. Scores can range from 8 to 40, and higher scores indicate greater use. (NCT02376257)
Timeframe: Week 2 and Week 3
Intervention | units on a scale (Mean) | |
---|---|---|
Week 2 | Week 3 | |
100 mg Modafinil | 20.5 | 24.3 |
250 mg DCS | 23.3 | 26.4 |
Placebo | 24.8 | 25.7 |
"Cephalon created the Excessive Sleepiness Symptom Rating Form to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(Tiredness, Fatigue, Sleepiness, Lack of energy, Trouble paying attention, Forgetfulness, Trouble staying organized) each on an 11-point Likert scale(0=no problem at all 10=as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment (measuring severity) of each of these 7 symptoms using the same 11-point scale. Change from Baseline to 12 Weeks is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: Baseline and 12 weeks following start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -2.2 |
Placebo | -1.3 |
"Cephalon created the Excessive Sleepiness Symptom Rating Form to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(Tiredness, Fatigue, Sleepiness, Lack of energy, Trouble paying attention, Forgetfulness, Trouble staying organized) each on an 11-point Likert scale(0=no problem at all 10=as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment (measuring severity) of each of these 7 symptoms using the same 11-point scale. Change from Baseline to 2 Weeks is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: Baseline and 2 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.6 |
Placebo | -1.2 |
"Cephalon created the Excessive Sleepiness Symptom Rating Form to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(Tiredness, Fatigue, Sleepiness, Lack of energy, Trouble paying attention, Forgetfulness, Trouble staying organized) each on an 11-point Likert scale(0=no problem at all 10=as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment (measuring severity) of each of these 7 symptoms using the same 11-point scale. Change from Baseline to 4 Weeks is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: Baseline and 4 weeks following start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -2.1 |
Placebo | -1.1 |
"Cephalon created the Excessive Sleepiness Symptom Rating Form to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(Tiredness, Fatigue, Sleepiness, Lack of energy, Trouble paying attention, Forgetfulness, Trouble staying organized) each on an 11-point Likert scale(0=no problem at all 10=as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment (measuring severity) of each of these 7 symptoms using the same 11-point scale. Change from Baseline to 8 Weeks is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: baseline and 8 weeks following start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.8 |
Placebo | -0.9 |
"The Excessive Sleepiness Symptom Rating Form was used to assess symptoms of excessive sleepiness. Patients rate 7 symptoms(tiredness, fatigue, sleepiness, lack of energy, trouble paying attention, forgetfulness, trouble staying organized) on an 11-point Likert scale (0 = no problem at all to 10 = as bad as you can imagine). ES Symptom Rating Form was designed to follow the response to treatment measuring severity of each of these 7 symptoms using the same 11-point scale. Change from Baseline to Endpoint (12 weeks or last baseline observation) is presented only for the symptom of Sleepiness." (NCT00518986)
Timeframe: Baseline and Endpoint (12 weeks or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.8 |
Placebo | -1.4 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and 12 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.1 |
Placebo | -0.3 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and 2 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -0.6 |
Placebo | 0.0 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and 4 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.0 |
Placebo | -0.6 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and 8 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -0.9 |
Placebo | -0.2 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The Interference Score consists of 6 questions that ask subjects to rate on a 0 to 10 scale how during the past 24 hours fatigue has interfered with their general activity, mood, walking ability, normal work, relations with other people, and enjoyment of life. The scores are averaged (0-10) for the Interference Score. (NCT00518986)
Timeframe: Baseline and at endpoint (12 weeks or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -0.9 |
Placebo | -0.3 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 12 weeks. (NCT00518986)
Timeframe: Baseline and 12 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -10.5 |
Placebo | -3.3 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 2 weeks. (NCT00518986)
Timeframe: Baseline and 2 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -6.1 |
Placebo | -0.9 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 4 weeks. (NCT00518986)
Timeframe: Baseline and 4 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -9.5 |
Placebo | -5.8 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 8 weeks. (NCT00518986)
Timeframe: Baseline and 8 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -8.8 |
Placebo | -3.0 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 12. (NCT00518986)
Timeframe: 12 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.4 |
Placebo | -0.6 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 2. (NCT00518986)
Timeframe: Baseline and 2 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.1 |
Placebo | -0.2 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 4. (NCT00518986)
Timeframe: Baseline and 4 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.2 |
Placebo | -0.8 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 8. (NCT00518986)
Timeframe: Baseline and 8 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.2 |
Placebo | -0.3 |
ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to 12 weeks are summarized. (NCT00518986)
Timeframe: 12 weeks (or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -6.8 |
Placebo | -4.8 |
ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to two weeks are summarized. (NCT00518986)
Timeframe: Baseline and 2 weeks following start of study drug administration
Intervention | Unit on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -4.8 |
Placebo | -3.8 |
ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to 4 weeks are summarized. (NCT00518986)
Timeframe: Baseline and 4 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -5.5 |
Placebo | -4.2 |
ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to 8 weeks are summarized. (NCT00518986)
Timeframe: Baseline and 8 weeks after start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -6.0 |
Placebo | -4.8 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. The change in total score from baseline to 12 weeks is presented here. (NCT00518986)
Timeframe: baseline and 12 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 2.6 |
Placebo | 1.6 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. The change in total score from baseline to 2 weeks is presented here. (NCT00518986)
Timeframe: baseline and 2 weeks following start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 1.7 |
Placebo | 1.1 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. The change in total score from baseline to 4 weeks is presented here. (NCT00518986)
Timeframe: baseline and 4 weeks following start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 2.2 |
Placebo | 1.4 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. The change in total score from baseline to 8 weeks is presented here. (NCT00518986)
Timeframe: baseline and 8 weeks following start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 2.2 |
Placebo | 1.4 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum of 2 maximum of 120) was calculated from the responses. The change in total score from baseline to Endpoint (12 weeks or last observation after baseline) is presented here. (NCT00518986)
Timeframe: Baseline and endpoint (12 weeks after start of study drug or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 2.3 |
Placebo | 1.5 |
MWT measures ability of subject to remain awake. Subjects instructed to try and remain awake during series of four 30-minute periods (0900, 1100, 1300, and 1500) reclining in dark room. Each period was terminated immediately after sleep onset or at end of 30 minutes if no sleep occured. If subject fell asleep, they were awakened and not allowed to sleep for remainder of that 30 minute period. Change from Baseline to 12 weeks in mean sleep latency (measured in minutes)averaged from each of the four testing intervals was measured. The poorest outcome was 0 minutes the best was 30 minutes. (NCT00518986)
Timeframe: baseline and 12 weeks (or last observation after baseline)
Intervention | Minutes (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 2.5 |
Placebo | 1.4 |
MWT measures ability of subject to remain awake. Subjects instructed to try and remain awake during series of four 30-minute periods (0900, 1100, 1300, and 1500) reclining in dark room. Each period was terminated immediately after sleep onset or at end of 30 minutes if no sleep occured. If subject fell asleep, they were awakened and not allowed to sleep for remainder of that 30 minute period. Change from Baseline to 4 weeks in mean sleep latency (measured in minutes)averaged from each of the four testing intervals was measured. The poorest outcome was 0 minutes the best was 30 minutes. (NCT00518986)
Timeframe: baseline and 4 weeks
Intervention | Minutes (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 2.7 |
Placebo | -0.1 |
MWT measures ability of subject to remain awake. Subjects instructed to try and remain awake during series of four 30-minute periods (0900, 1100, 1300, and 1500) reclining in dark room. Each period was terminated immediately after sleep onset or at end of 30 minutes if no sleep occured. If subject fell asleep, they were awakened and not allowed to sleep for remainder of that 30 minute period. Change from Baseline to 8 weeks in mean sleep latency (measured in minutes)averaged from each of the four testing intervals was measured. The poorest outcome was 0 minutes the best was 30 minutes. (NCT00518986)
Timeframe: Baseline and 8 weeks following start of study drug administration
Intervention | Minutes (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 2.1 |
Placebo | 1.2 |
MWT measures ability of subject to remain awake. Subjects instructed to try and remain awake during series of 4 30-minute periods (0900, 1100, 1300, and 1500) reclining in dark room. Each period was terminated immediately after sleep onset or at end of 30 minutes if no sleep occurred. If subject fell asleep, they were awakened and not allowed to sleep for remainder of that 30 minute period. Change from Baseline to Endpoint (12 weeks or last observation after baseline) in mean sleep latency averaged from the 4 intervals was measured. Poorest outcome was 0 minutes the best was 30 minutes. (NCT00518986)
Timeframe: Baseline and 12 weeks (or last observation after baseline)
Intervention | Minutes (Mean) |
---|---|
Armodafinil 200 mg/Day | 2.6 |
Placebo | 1.1 |
"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. The MOS-CF6 responses includes 6 choices, ranging from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to 12 weeks." (NCT00518986)
Timeframe: baseline and 12 weeks following start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 3.3 |
Placebo | 2.4 |
"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. The MOS-CF6 responses includes 6 choices, ranging from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to 2 weeks." (NCT00518986)
Timeframe: baseline and 2 weeks
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 2.0 |
Placebo | 1.9 |
"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. The MOS-CF6 responses includes 6 choices, ranging from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to 4 weeks." (NCT00518986)
Timeframe: baseline and 4 weeks following start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 3.4 |
Placebo | 2.4 |
"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning as follows: confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. The MOS-CF6 responses includes 6 choices, ranging from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to 8 weeks." (NCT00518986)
Timeframe: baseline and 8 weeks following start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 3.3 |
Placebo | 2.1 |
"The MOS-CF6 assesses self-reported cognitive function. Items were selected to cover 6 relevant aspects of cognitive functioning:confusion, concentration/thinking, attention, memory, reasoning, problem-solving, and processing speed. Responses range from none of the time to all of the time. The MOS-CF6 is scored by summing responses across the 6 items and converting the total to a 0 - 100 point scale, with the higher score indicating better cognitive functioning. Data is presented showing the change in score from baseline to Endpoint (12 weeks or last observation after baseline)." (NCT00518986)
Timeframe: Baseline and Endpoint (12 weeks or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | 3.2 |
Placebo | 2.4 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with >= 7 indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. This measure compares the change in score from baseline to Week 12 (or last observation after baseline). (NCT00518986)
Timeframe: Baseline and 12 weeks or last observation after baseline
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -1.3 |
Placebo | -0.7 |
For this key secondary outcome the ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The change in ESS total score from baseline to Endpoint (12 weeks or last observation after baseline) are summarized. (NCT00518986)
Timeframe: Baseline and 12 weeks (or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -6.5 |
Placebo | -4.6 |
The Brief Fatigue Inventory (BFI) is a subjective-completed tool for the assessment of the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The total score is calculated by taking the sum of all 9 rating scales for a minimum score of 0 and a maximum score of 90. This assessment examines the difference in total BFI score from Baseline to 12 weeks or last observation after baseline. (NCT00518986)
Timeframe: Baseline and 12 weeks following start of study drug administration or last recorded observation
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 200 mg/Day | -8.9 |
Placebo | -3.8 |
The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. The results for the number of participants who responded to each item on the full scale at 4 weeks are presented. (NCT00518986)
Timeframe: 4 weeks after start of treatment
Intervention | Participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
Armodafinil 200 mg/Day | 15 | 34 | 26 | 32 | 3 | 1 | 0 |
Placebo | 11 | 21 | 32 | 37 | 5 | 2 | 0 |
The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. Proportion of responders who had at least minimal improvement in CGI-C ratings (as related to sleepiness) were assessed. (NCT00518986)
Timeframe: 12 weeks after beginning treatment
Intervention | Participants (Number) | |
---|---|---|
At least minimal improvement | No improvement | |
Armodafinil 200 mg/Day | 69 | 27 |
Placebo | 53 | 42 |
The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. The results for the number of participants who responded to each item on the full scale at 12 weeks are presented. (NCT00518986)
Timeframe: 12 weeks after starting study drug treatment
Intervention | Participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
Armodafinil 200 mg/Day | 27 | 20 | 22 | 22 | 4 | 1 | 0 |
Placebo | 11 | 22 | 20 | 34 | 7 | 1 | 0 |
"The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. Proportion of responders who had at least minimally improved in CGI-C ratings (as related to sleepiness) at 4 weeks were assessed." (NCT00518986)
Timeframe: 4 weeks after beginning study drug treatment
Intervention | Participants (Number) | |
---|---|---|
At least minimal improvement | No improvement | |
Armodafinil 200 mg/Day | 75 | 36 |
Placebo | 64 | 44 |
"The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. Proportion of responders who had at least minimally improved in CGI-C ratings (as related to sleepiness) at 8 weeks were assessed." (NCT00518986)
Timeframe: 8 weeks after beginning study drug treatment
Intervention | Participants (Number) | |
---|---|---|
At least minimal improvement | No improvement | |
Armodafinil 200 mg/Day | 76 | 28 |
Placebo | 52 | 46 |
The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates 7 responses: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. The results for the number of participants who responded to each item on the full scale at 8 weeks are presented. (NCT00518986)
Timeframe: 8 weeks after start of study drug treatment
Intervention | Participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Very much improved | Much improved | Minimally improved | No change | Minimally worse | Much worse | Very much worse | |
Armodafinil 200 mg/Day | 16 | 39 | 21 | 26 | 1 | 1 | 0 |
Placebo | 11 | 19 | 22 | 37 | 7 | 2 | 0 |
"The CGI-C is a clinician's rating of disease severity compared with baseline as assessed by Clinical Global Impression of Severity (CGI-S). CGI-C rates improvement by 7 categories: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse. CGI-S measured 7 categories of illness as well: normal, borderline ill, mildly ill, moderately ill, markedly ill, severely ill, among most extremely ill. Proportion of responders who had at least minimally improved in CGI-C ratings (as related to sleepiness) were assessed." (NCT00518986)
Timeframe: 12 weeks (or last observation after baseline)
Intervention | Participants (Number) | |
---|---|---|
At least minimal improvement | No improvement | |
Armodafinil 200 mg/Day | 78 | 35 |
Placebo | 59 | 53 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 12 or last observation after baseline. (NCT00518986)
Timeframe: 12 weeks after start of study drug administration (or last observation after baseline)
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 63 | 49 |
Placebo | 56 | 55 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 12. (NCT00518986)
Timeframe: 12 weeks after start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 55 | 41 |
Placebo | 48 | 47 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 2. (NCT00518986)
Timeframe: 2 weeks after start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 62 | 48 |
Placebo | 43 | 65 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 4. (NCT00518986)
Timeframe: 4 weeks after start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 62 | 49 |
Placebo | 57 | 51 |
The Brief Fatigue Inventory (BFI) assesses the impact of fatigue on daily functioning. Simple numeric rating scales from 0 to 10 are used. The higher scores are associated with more severe fatigue, with any score >= 7 considered to be indicative of severe fatigue. The worst daily fatigue score reports the outcome of a single item on the BFI that rates the worst fatigue experienced over the day on a scale from 0 to 10 with 0 being no fatigue and 10 being most severe. Subjects were considered responders if the final Worst Fatigue Score was < 7 at Week 8. (NCT00518986)
Timeframe: 8 weeks after start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 63 | 41 |
Placebo | 42 | 56 |
ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The number of responders who had a total ESS score < 10 and the number of non-responders with a total score >= 10 at 12 weeks are presented. (NCT00518986)
Timeframe: 12 weeks
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 65 | 31 |
Placebo | 47 | 48 |
ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The number of responders who had a total ESS score < 10 and the number of non-responders with a total score >= 10 at 2 weeks are presented. (NCT00518986)
Timeframe: 2 weeks
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 54 | 53 |
Placebo | 40 | 64 |
ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The number of responders who had a total ESS score < 10 and the number of non-responders with a total score >= 10 at 4 weeks are presented. (NCT00518986)
Timeframe: 4 weeks
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 59 | 52 |
Placebo | 45 | 63 |
ESS score is based on responses to questions (self administered) that assessed the propensity of the subject to fall asleep in 8 everyday situations (sitting and reading, talking to someone, being stopped in traffic, etc.) Scores for the ESS range from 0 to 24, with a higher score indicating greater daytime sleepiness. The number of responders who had a total ESS score < 10 and the number of non-responders with a total score >= 10 at 8 weeks are presented. (NCT00518986)
Timeframe: 8 weeks
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 64 | 39 |
Placebo | 47 | 51 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. A responder analysis defining responders as patients with a total score > 17.9 at 12 weeks is presented here. (NCT00518986)
Timeframe: 12 weeks following the start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 43 | 51 |
Placebo | 28 | 66 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum=2 maximum = 120) was calculated from the responses. A responder analysis defining responders as patients with a total score > 17.9 at 4 weeks is presented here. (NCT00518986)
Timeframe: 4 weeks following start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 45 | 60 |
Placebo | 24 | 79 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score was calculated from the responses (minimum = 2 maximum = 120). A responder analysis defining responders as patients with a total score > 17.9 at 8 weeks is presented here. (NCT00518986)
Timeframe: 8 weeks following start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 36 | 65 |
Placebo | 20 | 77 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum=2 maximum=120) was calculated from the responses. A responder analysis defining responders as patients with a total score > 17.9 at 2 weeks is presented here. (NCT00518986)
Timeframe: 2 weeks following start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 30 | 75 |
Placebo | 19 | 84 |
The FOSQ is a self-administered questionnaire that assess the impact of excessive sleepiness on functional outcomes relevant to daily behaviors. The questionnaire contains 30 questions each rated from 1 to 4 (1 indicating extreme difficulty 4 indicating no difficulty, or 0 indicating not applicable). A total score (minimum = 2 maximum = 120) was calculated from the responses. A responder analysis defining responders as patients with a total score > 17.9 at Endpoint (12 weeks or last observation after baseline) is presented. (NCT00518986)
Timeframe: Endpoint (week 12 or last observation after baseline)
Intervention | Participants (Number) | |
---|---|---|
Responders | Non-responders | |
Armodafinil 200 mg/Day | 49 | 61 |
Placebo | 30 | 78 |
The HAM-A is a clinician-rated 14 item scale that provides an overall measure of global anxiety, including psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 - 56, where less than 17 indicates mild anxiety, 18 - 24 mild to moderate anxiety and 25-30 moderate to severe. The data presented here summarizes the change in HAM-A score from Baseline to 4 Weeks (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -3.6 |
Placebo | -3.5 |
The HAM-A is a clinician-rated 14 item scale that provides an overall measure of global anxiety, including psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 - 56, where less than 17 indicates mild anxiety, 18 - 24 mild to moderate anxiety and 25-30 moderate to severe. The data presented here summarizes the change in HAM-A score from Baseline to 8 Weeks (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -4.7 |
Placebo | -4.4 |
The HAM-A is a clinician-rated 14 item scale that provides an overall measure of global anxiety, including psychic (mental agitation and psychological distress) and somatic (physical complaints related to anxiety) symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0 - 56, where less than 17 indicates mild anxiety, 18 - 24 mild to moderate anxiety, 25-30 moderate to severe, >30 very severe. The data presented here summarizes the change in HAM-A score from Baseline to Endpoint (8 weeks or last observation after baseline). (NCT00481195)
Timeframe: baseline and 8 weeks (or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -4.1 |
Placebo | -3.9 |
The MADRS is a 10-item scale to evaluate the overall severity of a patient's depressive symptoms, that is completed by the physician. The rating scale makes use of both observational clues as to the subject's level of depression (eg. apparent sadness) and verbal indicators of depression expressed by the patient. Each of the 10 items is graded on a 6-point scale with anchors at 2 point intervals. Total scores range from 0 to 60, with the higher number indicating more severe symptoms of depression. Here we present data summarizing the change in MADRS from Baseline to Endpoint. (NCT00481195)
Timeframe: Baseline and Endpoint (8 weeks following the start of study drug administration or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -12.3 |
Placebo | -10.2 |
The Q-LES-Q-SF is an instrument designed to measure general activities of daily living. It is a patient-rated quality of life questionnaire and consists of 16 items, but only the first 14 are included in the total score. Each item is rated by the patient on a scale from 1 - 5 (1=very poor, 2=poor, 3=fair, 4=good, and 5=very good). The minimum score is 14 and the maximum score is 70, with lower scores indicating poorer quality of life. The data presented here summarizes the change in score from baseline to endpoint (8 weeks or last observation after baseline). (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | 8.2 |
Placebo | 7.4 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Endpoint (Week 8 or last observation after baseline). (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -7.0 |
Placebo | -6.5 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Item 4 assesses hypersomnia on a scale from 0 (sleeps no longer than 7-8 hours a night) to 3 (sleeps longer than 12 hours in 24 hour period). The data presented here summarizes the change from baseline to Endpoint in the score of Item 4 assessing hypersomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -0.4 |
Placebo | -0.2 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Items 1 - 3 assess sleep onset insomnia, mid-nocturnal insomnia, and early morning insomnia respectively each on a 0 - 3 scale. The data presented here summarizes the change from baseline to Endpoint in the combined score of these three items assessing insomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -1.6 |
Placebo | -1.2 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 1 (NCT00481195)
Timeframe: Baseline and 1 week following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -3.5 |
Placebo | -3.7 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 2 (NCT00481195)
Timeframe: Baseline and 2 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -5.0 |
Placebo | -4.1 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 3. (NCT00481195)
Timeframe: Baseline and 3 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -5.8 |
Placebo | -5.0 |
The MADRS is a 10-item scale to evaluate the overall severity of a patient's depressive symptoms, that is completed by the physician. The rating scale makes use of both observational clues as to the subject's level of depression (eg. apparent sadness) and verbal indicators of depression expressed by the patient. Each of the 10 items is graded on a 6-point scale with anchors at 2 point intervals. Total scores range from 0 to 60, with the higher number indicating more severe symptoms of depression. Here we present data summarizing the difference in MADRS score from Baseline to Week 4. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -9.6 |
Placebo | -8.9 |
The Q-LES-Q-SF is an instrument designed to measure general activities of daily living. It is a patient-rated quality of life questionnaire and consists of 16 items, but only the first 14 are included in the total score. Each item is rated by the patient on a scale from 1 - 5 (1=very poor, 2=poor, 3=fair, 4=good, and 5=very good). The minimum score is 14 and the maximum score is 70, with lower scores indicating poorer quality of life. The data presented here summarizes the change in score from baseline to 4 weeks. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | 5.9 |
Placebo | 4.6 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 4. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -6.4 |
Placebo | -5.6 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Item 4 assesses hypersomnia on a scale from 0 (sleeps no longer than 7-8 hours a night) to 3 (sleeps longer than 12 hours in 24 hour period). The data presented here summarizes the change from baseline to week 4 in the score of Item 4 assessing hypersomnia. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -0.2 |
Placebo | -0.2 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Items 1 - 3 assess sleep onset insomnia, mid-nocturnal insomnia, and early morning insomnia respectively each on a 0 - 3 scale. The data presented here summarizes the change from baseline to week 4 in the combined score of these three items assessing insomnia. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -1.2 |
Placebo | -1.1 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 6. (NCT00481195)
Timeframe: Baseline and 6 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -7.8 |
Placebo | -6.7 |
The MADRS is a 10-item scale to evaluate the overall severity of a patient's depressive symptoms, that is completed by the physician. The rating scale makes use of both observational clues as to the subject's level of depression (eg. apparent sadness) and verbal indicators of depression expressed by the patient. Each of the 10 items is graded on a 6-point scale with anchors at 2 point intervals. Total scores range from 0 to 60, with the higher number indicating more severe symptoms of depression. Here we present data summarizing the difference in MADRS score from Baseline to Week 8. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -13.4 |
Placebo | -11.0 |
The Q-LES-Q-SF is an instrument designed to measure general activities of daily living. It is a patient-rated quality of life questionnaire and consists of 16 items, but only the first 14 are included in the total score. Each item is rated by the patient on a scale from 1 - 5 (1=very poor, 2=poor, 3=fair, 4=good, and 5=very good). The minimum score is 14 and the maximum score is 70, with lower scores indicating poorer quality of life. The data presented here summarizes the change in score from baseline to 8 weeks. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | 10.1 |
Placebo | 8.5 |
The QIDS-SR16 is a 16-item rating scale of depressive symptoms completed by the patient at each visit. It is a shorter version of the IDS-C30 that is completed by the patient rather than the examiner. The total score ranges from 0 to 27 (higher score signifies more severe depression) and is obtained by adding the scores for each of the 9 depression symptom domains of the DSM IV. The data presented here summarizes the change in QIDS-SR16 from Baseline to Week 8. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -8.2 |
Placebo | -7.6 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Item 4 assesses hypersomnia on a scale from 0 (sleeps no longer than 7-8 hours a night) to 3 (sleeps longer than 12 hours in 24 hour period). The data presented here summarizes the change from baseline to week 8 in the score of Item 4 assessing hypersomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -0.3 |
Placebo | -0.2 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. Items 1 - 3 assess sleep onset insomnia, mid-nocturnal insomnia, and early morning insomnia respectively each on a 0 - 3 scale. The data presented here summarizes the change from baseline to week 8 in the combined score of these three items assessing insomnia. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -2.0 |
Placebo | -1.6 |
The IDS C30 is a standardized 30 item, clinician rated scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Endpoint (either week 8 or the last observation after baseline) in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 8 weeks from start of study drug administration (or last observation after baseline)
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -15.6 |
Placebo | -12.5 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 1 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 1 week following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -6.5 |
Placebo | -4.8 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 2 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 2 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -10.0 |
Placebo | -7.3 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 3 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 3 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -13.1 |
Placebo | -10.7 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 4 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -13.7 |
Placebo | -12.1 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 6 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 6 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -16.7 |
Placebo | -13.7 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data presented here summarizes the change from baseline to Week 8 in the total score of the IDS-C30. (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
Intervention | Units on a scale (Least Squares Mean) |
---|---|
Armodafinil 150 mg/Day | -17.8 |
Placebo | -14.8 |
"The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a response (> 50% decrease from baseline in total score)." (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)
Intervention | Participants (Number) | |
---|---|---|
Response | No Response | |
Armodafinil 150 mg/Day | 46 | 78 |
Placebo | 47 | 76 |
"The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a sustained remission (total score <= 11 that persists over the four week period from Week 4 to Week 8)." (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)
Intervention | Participants (Number) | |
---|---|---|
Sustained Remission | No Sustained Remission | |
Armodafinil 150 mg/Day | 13 | 111 |
Placebo | 8 | 115 |
"The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a sustained response (> 50% decrease from baseline in total score that persisted over the four week period between Week 4 and Week 8)." (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)
Intervention | Participants (Number) | |
---|---|---|
Sustained Response | No Sustained Response | |
Armodafinil 150 mg/Day | 23 | 101 |
Placebo | 17 | 106 |
The IDS C30 is a standardized 30 item, clinician rated, scale to assess the severity of a patient's depressive symptoms. The scale uses the 9 symptom domains of the DSM-IV criteria to measure symptom severity. The scores range from a minimum of 0 to a maximum score of 84. The higher the score the more severe the symptoms of depression. The data here summarizes the number of subjects in each treatment group who achieved a remission (total score <=11). (NCT00481195)
Timeframe: Baseline, 4 and 8 weeks following start of study drug administration (or last observation after baseline)
Intervention | Participants (Number) | |
---|---|---|
Remission | No Remission | |
Armodafinil 150 mg/Day | 30 | 94 |
Placebo | 22 | 101 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Endpoint are presented." (NCT00481195)
Timeframe: Baseline and 8 weeks (or last observation after baseline)
Intervention | Participants (Number) | |
---|---|---|
Responder | Non Responder | |
Armodafinil 150 mg/Day | 64 | 60 |
Placebo | 60 | 62 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 1 are presented." (NCT00481195)
Timeframe: Baseline and 1 week following the start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responder | Non Responder | |
Armodafinil 150 mg/Day | 12 | 107 |
Placebo | 12 | 105 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 2 are presented." (NCT00481195)
Timeframe: Baseline and 2 weeks following the start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responder | Non Responder | |
Armodafinil 150 mg/Day | 25 | 83 |
Placebo | 26 | 84 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 3 are presented." (NCT00481195)
Timeframe: Baseline and 3 weeks following the start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responder | Non Responder | |
Armodafinil 150 mg/Day | 38 | 64 |
Placebo | 32 | 68 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 4 are presented." (NCT00481195)
Timeframe: Baseline and 4 weeks following the start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responder | Non Responder | |
Armodafinil 150 mg/Day | 46 | 53 |
Placebo | 42 | 55 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 6 are presented." (NCT00481195)
Timeframe: Baseline and 6 weeks following the start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responder | Non Responder | |
Armodafinil 150 mg/Day | 47 | 45 |
Placebo | 43 | 49 |
"CGI-BP is a standardized, clinician-rated assessment which allows the clinician to rate the bipolar illness at various time points compared with baseline. At Screening and Baseline visits the physician rated the severity of the illness using 7 categories (1=normal through 7=very severely ill). At subsequent visits the clinician assessed the change in severity of the condition using 7 categories (1=very much improved through 7=very much worse). Subjects were considered responders if they had a rating of much improved or very much improved. The number of responders at Week 8 are presented." (NCT00481195)
Timeframe: Baseline and 8 weeks following the start of study drug administration
Intervention | Participants (Number) | |
---|---|---|
Responder | Non Responder | |
Armodafinil 150 mg/Day | 52 | 37 |
Placebo | 47 | 41 |
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
Placebo Adjunct | 12.57 | 9.08 | -3.49 |
10 reviews available for modafinil and Depression, Involutional
Article | Year |
---|---|
The Potential Procognitive Effects of Modafinil in Major Depressive Disorder: A Systematic Review.
Topics: Adult; Central Nervous System Stimulants; Cognition Disorders; Controlled Clinical Trials as Topic; | 2019 |
The role of eugeroics in the treatment of affective disorders.
Topics: Adult; Antidepressive Agents; Central Nervous System Stimulants; Depressive Disorder, Major; Evidenc | 2020 |
The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Dextroamphetami | 2017 |
Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials.
Topics: Antidepressive Agents; Antimanic Agents; Benzhydryl Compounds; Bipolar Disorder; Depressive Disorder | 2013 |
Stimulants for depression: On the up and up?
Topics: Amphetamine; Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System S | 2016 |
The role of dopaminergic agents in improving quality of life in major depressive disorder.
Topics: Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Depressive Disorder, Major; Dopa | 2009 |
[Modafinil in the treatment of depression].
Topics: Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System Stimulants; De | 2012 |
Executive dysfunction in major depressive disorder.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognition Disorders; Depressive Disorder, M | 2005 |
Pharmacological approaches to the treatment of residual symptoms.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Benzhydryl Compounds; Benzodiazepines; Central | 2006 |
Symptoms of fatigue and sleepiness in major depressive disorder.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Bupropion; Ce | 2006 |
15 trials available for modafinil and Depression, Involutional
Article | Year |
---|---|
A multi-pronged investigation of option generation using depression, PET and modafinil.
Topics: Adult; Cross-Over Studies; Depression; Depressive Disorder, Major; Dopamine; Humans; Modafinil; Posi | 2022 |
Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial.
Topics: Adult; Benzhydryl Compounds; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Drug | 2014 |
Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Benzhydryl Compounds; Cytoc | 2015 |
Examining the efficacy of d-cycloserine to augment therapeutic learning in depression.
Topics: Antimetabolites; Benzhydryl Compounds; Cognitive Behavioral Therapy; Combined Modality Therapy; Cycl | 2016 |
A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Continuous Positive | 2010 |
Modafinil reduces microsleep during partial sleep deprivation in depressed patients.
Topics: Adult; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Double-B | 2010 |
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antimanic Agents; Benzhydryl Compounds; Benzodiazepi | 2010 |
Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimul | 2011 |
An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy.
Topics: Adolescent; Adult; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; D | 2003 |
Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Di | 2003 |
A prospective trial of modafinil as an adjunctive treatment of major depression.
Topics: Adult; Aged; Antidepressive Agents; Benzhydryl Compounds; Depressive Disorder, Major; Diagnostic and | 2004 |
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2004 |
A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2005 |
Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2006 |
Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde | 2007 |
21 other studies available for modafinil and Depression, Involutional
Article | Year |
---|---|
High-dose armodafinil in treatment-refractory bipolar depression.
Topics: Aged; Benzhydryl Compounds; Bipolar Disorder; COVID-19; Depressive Disorder, Major; Female; Humans; | 2023 |
[Use of Modafinil in Co-existing Major Depression and ErectileDysfunction: A Case Report].
Topics: Adult; Central Nervous System Stimulants; Depressive Disorder, Major; Drug Administration Schedule; | 2019 |
Innovation in the treatment of bipolar depression.
Topics: Benzhydryl Compounds; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Male; Modafinil; | 2014 |
When positive isn't positive: the hopes and disappointments of clinical trials.
Topics: Benzhydryl Compounds; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Male; Modafinil; | 2014 |
Evaluation of the potential for pharmacokinetic drug-drug interaction between armodafinil and carbamazepine in healthy adults.
Topics: Adult; Anticonvulsants; Benzhydryl Compounds; Bipolar Disorder; Carbamazepine; Cytochrome P-450 CYP3 | 2015 |
A primer on confidence intervals in psychopharmacology.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents; Benzhydryl Compounds; Confidence Intervals; Curr | 2015 |
Is there a role for psychostimulants in old age depression and apathy?
Topics: Aged; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Dis | 2009 |
Augmentation of dopaminergic agents for major depressive disorder.
Topics: Administration, Oral; Benzhydryl Compounds; Central Nervous System Stimulants; Combined Modality The | 2009 |
Modafinil use in patients with a primary psychiatric illness.
Topics: Adult; Affect; Arousal; Benzhydryl Compounds; Bipolar Disorder; Brain Injury, Chronic; Central Nervo | 2010 |
The use of dopaminergic and stimulant drugs for the treatment of depression.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hype | 2012 |
Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient.
Topics: Aged; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cachexia; Central Nervous System Stimu | 2002 |
Modafinil as an alternative to light therapy for winter depression.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Humans; Male; M | 2004 |
Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.
Topics: Benzhydryl Compounds; Blood Pressure; Cataplexy; Central Nervous System Stimulants; Comorbidity; Dep | 2004 |
A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy.
Topics: Adult; Anxiety; Benzhydryl Compounds; Central Nervous System Stimulants; Chemotherapy, Adjuvant; Dem | 2005 |
Modafinil-induced reversible hyperkinetic nondystonic movement disorder in a patient with major depressive disorder.
Topics: Aged; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimula | 2006 |
Serious adverse events and the modafinil augmentation study.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Drug Synergism; | 2006 |
Using psychostimulants for treating residual symptoms in major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimul | 2007 |
Ultra short manic-like episodes after antidepressant augmentation with modafinil.
Topics: Antidepressive Agents; Benzhydryl Compounds; Bipolar Disorder; Central Nervous System Stimulants; De | 2008 |
Methylphenidate and depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Delayed-Action Prepa | 2008 |
Visual and coenesthetic hallucinations associated with modafinil.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Hallucinations; | 2008 |
Modafinil monotherapy in depression.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Humans; Male; M | 2002 |